With a market cap of $11.3 billion, Viatris Inc. (VTRS) is a global pharmaceutical company headquartered in Pennsylvania with operations in over 165 countries. Its portfolio spans generic and branded medicines, biosimilars, and APIs, covering key therapeutic areas like cardiovascular, oncology, CNS, women’s health, and gastroenterology.

Companies worth $10 billion or more are generally described as "large-cap stocks." Viatris fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the specialty & generic drug manufacturing industry.

As Lithium Americas Stock Doubles on Trump Stake Bid, Is It Too Late to Buy LAC?

As Intel Pops on Potential Apple Stake, Options Data Tells Us INTC Stock Could Be Headed Here Next

Is This Stock the Next Trillion-Dollar Opportunity in AI and Energy?

Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else.

However, it’s not all sunshine and rainbows for the stock. Viatris stock touched its 52-week high of $13.55 on Nov. 25, 2024, and is currently trading 30% below that peak. Over the past three months, VTRS stock has surged 6.8%, trailing the broader Nasdaq Composite’s ($NASX) 12.1% rise over the same time frame.

Viatris has continued to deliver a sluggish performance over the longer horizon, with shares down 23.8% year-to-date and 15.8% over the past 52 weeks, sharply lagging the Nasdaq’s gains of 15.9% in 2025 and 23.8% over the past year.

The stock has also shown persistent technical weakness, remaining below its 200-day moving average since mid-January and slipping under the 50-day moving average more recently, reinforcing a bearish outlook.

On Aug. 7, Viatris posted its fiscal 2025 second-quarter results, and its shares surged 7.3%. It reported revenues of $3.58 billion, down 6% year over year on a reported basis and 2% lower on a divestiture-adjusted operational basis, with growth of about 3% excluding disruptions tied to its Indore facility. The company’s adjusted EPS came in at $0.62, down 10% and adjusted EBITDA slipped 11% to $1.08 billion.

Adding to the woes, Viatris has significantly trailed its peer Sanofi's (SNY) 5.8% dip in 2025 and a 20.3% downtick over the past 52 weeks.

Among the eight analysts covering the VTRS stock, the consensus rating is a “Hold.” Its mean price target of $11.46 suggests a 20.8% upside potential from current price levels.

On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com